Drug intelligence / Profile preview

methyl prednisolonate

Development stage: Preclinical
Lead developer: Pfizer
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Topical, Systemic

Overview

Methyl prednisolonate is a synthetic steroid acid ester, derived from prednisolone by modifying its 17-ketol side chain. It is designed as an 'antedrug' to provide local anti-inflammatory activity while minimizing systemic side effects. Studies in rats indicate that it significantly reduces oxazolone-induced ear edema and exhibits anti-inflammatory effects without suppressing pituitary-adrenal function or causing liver glycogen depletion, unlike its parent compound, prednisolone. It also demonstrates weak membrane stabilization capacities in vitro.

Targets

GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on methyl prednisolonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methyl prednisolonate.

Explore the full profile